Dare Bioscience, Inc. Proceeds from Warrant Exercises
Dare Bioscience, Inc. (DARE) reported Proceeds from Warrant Exercises of $1.30 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2023-11-09
- Dare Bioscience, Inc. proceeds from warrant exercises for the quarter ending 2023-09-30 was $0.00.
- Dare Bioscience, Inc. proceeds from warrant exercises for the quarter ending 2023-06-30 was $0.00.
- Dare Bioscience, Inc. proceeds from warrant exercises for the quarter ending 2023-03-31 was $1.30M.
- Dare Bioscience, Inc. proceeds from warrant exercises for the quarter ending 2021-12-31 was $245.13K.
- Dare Bioscience, Inc. proceeds from warrant exercises for fiscal 2021 was $500.00K, a 72.22% decline from fiscal 2020.
- Dare Bioscience, Inc. proceeds from warrant exercises for fiscal 2020 was $1.80M.
| Period end | Proceeds from Warrant Exercises 3 month | Proceeds from Warrant Exercises 6 month | Proceeds from Warrant Exercises 9 month | Proceeds from Warrant Exercises 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $1.30M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.30M 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $1.30M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $245.13K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $449.60K derived: sum of 2 quarters · filed 2023-03-30 | $450.00K derived: sum of 3 quarters · filed 2023-03-30 | $500.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $204.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $204.87K derived: sum of 2 quarters · filed 2022-11-10 | $254.87K 10-Q · filed 2022-11-10 | $254.87K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $400.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $50.40K 10-Q · filed 2022-08-09 | $50.40K derived: sum of 3 quarters · filed 2022-08-09 | $171.40K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $50.00K 10-Q · filed 2022-05-12 | $50.00K derived: sum of 2 quarters · filed 2022-05-12 | $171.00K derived: sum of 3 quarters · filed 2022-05-12 | $171.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $121.00K derived: sum of 2 quarters · filed 2022-03-31 | $121.00K derived: sum of 3 quarters · filed 2022-03-31 | $1.80M 10-K · filed 2022-03-31 |
| 2020-09-30 | $121.00K 10-Q · filed 2020-11-12 | $121.00K derived: sum of 2 quarters · filed 2021-08-12 | $1.80M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.70M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1.70M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |